RT Journal Article
T1 Patients with Invasive Lobular Carcinoma Show a Significant Increase in IRS-4 Expression Compared to Infiltrative Ductal Carcinoma—A Histopathological Study
A1 Ortega, Miguel A.
A1 Fraile Martínez, Oscar
A1 García Montero, Cielo
A1 Borja Vergel, Sandra
A1 Torres Carranza, Diego
A1 Pekarek, Leonel
A1 Bravo Arribas, Coral
A1 De León Luis, Juan Antonio
A1 Sánchez Rojo, Cristina
A1 Álvarez Mon, Miguel Ángel
A1 García Honduvilla, Natalio
A1 Bujan, Julia
A1 Coca, Santiago
A1 Álvarez Mon, Melchor
A1 Saez, Miguel A.
A1 Guijarro, Luis G.
AB Background and Objectives: Breast cancer (BC) is the first diagnosed type of cancer and the second leading cause of cancer-related mortality in women. In addition, despite the improvement in treatment and survival in these patients, the global prevalence and incidence of this cancer are rising, and its mortality may be different according to the histological subtype. Invasive lobular carcinoma (ILC) is less common but entails a poorer prognosis than infiltrative ductal carcinoma (IDC), exhibiting a different clinical and histopathological profile. Deepening study on the molecular profile of both types of cancer may be of great aid to understand the carcinogenesis and progression of BC. In this sense, the aim of the present study was to explore the histological expression of Insulin receptor substrate 4 (IRS-4), cyclooxygenase 2 (COX-2), Cyclin D1 and retinoblastoma protein 1 (Rb1) in patients with ILC and IDC. Patients and Methods: Thus, breast tissue samples from 45 patients with ILC and from 45 subjects with IDC were analyzed in our study. Results: Interestingly, we observed that IRS-4, COX-2, Rb1 and Cyclin D1 were overexpressed in patients with ILC in comparison to IDC. Conclusions: These results may indicate a differential molecular profile between both types of tumors, which may explain the clinical differences among ILC and IDC. Further studies are warranted in order to shed light onto the molecular and translational implications of these components, also aiding to develop a possible targeted therapy to improve the clinical management of these patients.
PB MDPI
SN 1648-9144
YR 2022
FD 2022-05-28
LK https://hdl.handle.net/20.500.14352/72151
UL https://hdl.handle.net/20.500.14352/72151
LA eng
NO Comunidad de Madrid
NO HALEKULANI, S.L.
DS Docta Complutense
RD 10 abr 2025